Form 4: Summit Therapeutics CFO Ankur Dhingra Acquires 100,000 Shares

Ankur Dhingra, CFO of Summit Therapeutics Inc., purchased 100,000 shares of common stock at an average price of $3.75 on March 26, 2024.

Summary

• On March 26, 2024, Ankur Dhingra, the Chief Financial Officer of Summit Therapeutics Inc., acquired 100,000 shares of the company's common stock.
• The shares were purchased at a weighted average price of $3.75, with individual transactions ranging from $3.74 to $3.76 per share.
• Following the transaction, Dhingra beneficially owns 354,958 shares indirectly through the Dhingra Family Revocable Trust.
• Dhingra disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CFO's purchase indicates confidence, but it's a single transaction and requires further context.

Positives

• The CFO's purchase of a significant number of shares could be interpreted as a sign of confidence in the company's future prospects.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

Insider buying is often seen as a positive signal, suggesting that a company's management believes the stock is undervalued. However, it's important to consider the overall context and not rely solely on insider transactions when making investment decisions.

Stakeholder Impact

• The CFO's stock purchase could positively influence shareholder sentiment.

Key Dates